SEC Filing Document

Company: Synergy CHC Corp.
Ticker: SNYR
CIK: 1562733
Filing Type: S-1
Document Type: S-1
Date Filed: 2026-05-15
Accession Number: 0001213900-26-057939
Exchange: Nasdaq
SIC Code: 2833
SIC Description: Medicinal Chemicals & Botanical Products
URL: https://www.sec.gov/Archives/edgar/data/1562733/000121390026057939/ea0290954-s1_synergy.htm

Chunk 13 of 16
Word Count: 1468
Character Count: 9097

Document Content:

action, suit or proceeding, whether civil, criminal, administrative or investigative, except an action by or in the right of the corporation, by reason of the fact that he is or was a director, officer, employee or agent of the corporation, or is or was serving at the request of the corporation as a director, officer, employee or agent of another corporation, partnership, joint venture, trust or other enterprise, against expenses, including attorneys’ fees, judgments, fines and amounts paid in settlement actually and reasonably incurred by him in connection with the action, suit or proceeding if he: (a) is not liable pursuant to NRS 78.138; or (b) acted in good faith and in a manner which he reasonably believed to be in or not opposed to the best interests of the corporation, and, with respect to any criminal action or proceeding, had no reasonable cause to believe his conduct was unlawful.

NRS Section 78.7502(2) provides
that a corporation may indemnify any person who was or is a party or is threatened to be made a party to any threatened, pending or completed
action or suit by or in the right of the corporation to procure a judgment in its favor by reason of the fact that he is or was a director,
officer, employee or agent of the corporation, or is or was serving at the request of the corporation as a director, officer, employee
or agent of another corporation, partnership, joint venture, trust or other enterprise against expenses, including amounts paid in settlement
and attorneys’ fees actually and reasonably incurred by him in connection with the defense or settlement of the action or suit if
he: (a) is not liable pursuant to NRS 78.138; or (b) acted in good faith and in a manner which he reasonably believed to be
in or not opposed to the best interests of the corporation. Indemnification may not be made for any claim, issue or matter as to which
such a person has been adjudged by a court of competent jurisdiction, after exhaustion of all appeals there from, to be liable to the
corporation or for amounts paid in settlement to the corporation, unless and only to the extent that the court in which the action or
suit was brought or other court of competent jurisdiction determines upon application that in view of all the circumstances of the case,
the person is fairly and reasonably entitled to indemnity for such expenses as the court deems proper.

NRS Section 78.747 provides
that except as otherwise provided by specific statute, no director or officer of a corporation is individually liable for a debt or liability
of the corporation, unless the director or officer acts as the alter ego of the corporation. The court as a matter of law must determine
the question of whether a director or officer acts as the alter ego of a corporation.

Our amended and restated bylaws
provide that we will indemnify our directors, officers, employees and agents to the extent and in the manner permitted by the provisions
of the NRS, as amended from time to time, subject to any permissible expansion or limitation of such indemnification, as may be set forth
in any stockholders’ or directors’ resolution or by contract. Any repeal or modification of these provisions approved by our
stockholders will be prospective only and will not adversely affect any limitation on the liability of any of our directors or officers
existing as of the time of such repeal or modification. We are also permitted to apply for insurance on behalf of any director, officer,
employee or other agent for liability arising out of his actions, whether or not the NRS would permit indemnification.

We have entered into indemnification
agreements with each of our officers and directors, a form of which is filed as an exhibit to this Registration Statement.

These agreements require us
to indemnify these individuals to the fullest extent permitted under Nevada law against liabilities that may arise by reason of their
service to us, and to advance expenses incurred as a result of any proceeding against them as to which they could be indemnified.

Item 15.
Recent Sales of Unregistered Securities.

In the three years preceding
the filing of this registration statement, we have issued the following securities that were not registered under the Securities Act:

Pre-Funded Common Stock Purchase Warrant

On May 29, 2025, we satisfied
$12,713,858 of Company debt, previously owed to Knight Therapeutics International S.A. (“Knight”), through a combination of
(i) a $10,000,000 cash repayment, (ii) an early payment discount of $1,213,858, and (ii) a conversion of $1,500,000 into equity (the “Equity
Conversion”).

On May 29, 2025 (the “Initial Exercise Date”), we
issued a pre-funded common stock purchase warrant (the “Pre-Funded Warrant”) to purchase up to 428,570 shares of common
stock (each a “Pre-Funded Warrant Share”), to Knight, in connection with the Equity Conversion. The Pre-Funded Warrant expires
upon the earlier of the date the Pre-Funded Warrant is exercised in full, and May 29, 2026. The aggregate exercise price of the Pre-Funded
Warrant, except for a nominal exercise price of $0.00001 per Pre-Funded Warrant Share, was pre-funded to the Company on or prior to the
Initial Exercise Date and, consequently, no additional consideration (other than the nominal exercise price of $0.00001 per Pre-Funded
Warrant Share) shall be required to be paid by Knight to effect any exercise of the Pre-Funded Warrant. The Pre-Funded Warrant may be
exercised, in whole or in part, by means of a “cashless exercise.” The Pre-Funded Warrant provides that the warrant will be
automatically exercised via “cashless exercise” pursuant to Section 2(c) of the Pre-Funded  Warrant upon the closing
of the next sale of equity securities of the Company. We relied upon the exemption from registration provided by Section 4(a)(2) of the
Securities Act for transactions by an issuer not involving a public offering to issue the Pre-Funded Warrant.

Issuance in Connection with Consulting Services
Agreement

On April 9, 2025, the Company
entered into a Consulting Services Agreement (the “Consulting Agreement”) with FMW Media Works, LLC (the “Consultant”).
Pursuant to the terms of the Consulting Agreement, on July 7, 2025, the Company issued to the Consultant 60,000 shares of Company common
stock in consideration for services provided. The Company relied upon the exemption from registration provided by Section 4(a)(2) of the
Securities Act for transactions by an issuer not involving a public offering to issue the shares.

Warrant Issuance in Connection with Second
Amendment to Term Loan Credit Agreement

On March 24, 2026, the Company
entered into a second amendment (the “Second Amendment”) to its term loan credit agreement, dated May 30, 2025 (as previously
amended, the “Credit Agreement”, and as amended by the Second Amendment, the “Amended Credit Agreement”), with
ACP Agency, LLC (“ACP”), as administrative agent and collateral agent, and the lenders party thereto. In connection with the
Second Amendment, on March 24, 2026 the Company issued a common stock purchase warrant (the “Lender Warrant”) to Acme Credit
Partners Fund I, LP (the “Holder”), a lender under the Credit Agreement. The Lender Warrant provides the Holder the right
to purchase 3,000,000 shares of the Company’s common stock at an exercise price of $0.00001 per share. The Lender Warrant has a
ten-year term and becomes exercisable upon the occurrence of a “Qualified Event of Default,” defined as the occurrence of
any event of default under Section 8.1(a) of the Credit Agreement; the Lender Warrant terminates upon the indefeasible payment in full
of all secured obligations under the Credit Agreement and related loan documents. The Company issued the Lender Warrant in a transaction
not involving a public offering pursuant to Section 4(a)(2) of the Securities Act.

Warrant Issuance in Connection with ELOC Purchase
Agreement

As consideration for the Selling
Stockholder’s execution and delivery of the ELOC Purchase Agreement, the Company issued to the Selling Stockholder a warrant for
the purchase of 1,540,000 shares of the common stock at an exercise price of $0.01 per share, subject to adjustment. Under the warrant,
the Selling Stockholder may exercise the Warrant during the period commencing on May 8, 2026 and ending on 5:00 p.m. eastern standard
time on the date that is five (5) years after May 8, 2026. In addition, the Company will pay up to $20,000.00 to the Selling Stockholder’s
legal counsel for the Selling Stockholder’s expenses relating to the preparation of the ELOC Purchase Agreement. The Company issued
the warrant in a transaction not involving a public offering pursuant to Section 4(a)(2) of the Securities Act.

Item 16.
Exhibits and Financial Statement Schedules.

Exhibits

The following documents are
filed as exhibits to this registration statement:

Exhibit No. Description

3.1 Articles of Incorporation, as amended (incorporated by reference to Exhibit 3.1 to the Registration Statement on Form S-1, filed by Synergy CHC Corp. on September 16, 2024).